Paul A. Hopper is an entrepreneur and businessperson who founded 7 companies, notably: Imugene Ltd., Prescient Therapeutics Ltd. and Chimeric Therapeutics Ltd. (Australia) and who has been the head of 14 different companies. Presently, Paul A. Hopper is Executive Chairman of Imugene Ltd. (which he founded in 2012), Chairman for Vaxinia Pty Ltd. (a subsidiary of Imugene Ltd.), Executive Chairman at Arovella Therapeutics Ltd., Executive Chairman at Chimeric Therapeutics Ltd. (Australia) (which he founded in 2020) and Executive Chairman for Radiopharm Theranostics Ltd. Paul A. Hopper is also on the board of Biolife Science Ltd. and Managing Director at Cappello Group, Inc., MD, Head-Life Sciences & Biotechnology Group at Cappello Global LLC and Member of Pacific Council on International Policy.

He previously was Executive Chairman of CAQ Holdings Ltd., Executive Chairman for Botanix Pharmaceuticals Ltd., Independent Director at Scopus Biopharma, Inc. and Executive Chairman of Bioscience Oncology Pty Ltd. (a subsidiary of Scopus Biopharma, Inc.), Managing Director at Alpha Healthcare Ltd. (he founded the company), Executive Chairman for Viralytics Pty Ltd., President for Innovate Oncology, Inc., Managing Director at The Merchants Bank of New York, Managing Director at Avantogen Ltd., Chief Operating Officer & Director at Acuvax Ltd., Chairman-California Chapter at American Australian Association, Non-Executive Director at Prescient Therapeutics Ltd. and Lead Director at Polynoma LLC.

Paul A. Hopper received an undergraduate degree from The University of New South Wales.